Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
Public ClinicalTrials.gov record NCT05074498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Seamless Phase 1b/2a Double-blind, Randomized, Multiple Dose, Multi-center, Sequential Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TB006 in Patients With Mild to Severe Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006 (production of anti-TB006 antibody). Part 2 of this study will be conducted to determine the clinical efficacy of TB006 in participants with mild to severe Alzheimer's Disease.
Study identification
- NCT ID
- NCT05074498
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2021
- Primary completion
- Oct 12, 2022
- Completion
- Oct 12, 2022
- Last update posted
- Nov 17, 2023
2021 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 6
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Garden Grove | California | 92845 | — |
| Clinical Trial Site | San Diego | California | 92103 | — |
| Clinical Trial Site | Delray Beach | Florida | 33445 | — |
| Clinical Trial Site | Lady Lake | Florida | 32159 | — |
| Clinical Trial Site #1 | Maitland | Florida | 32751 | — |
| Clinical Trial Site | Maitland | Florida | 32751 | — |
| Clinical Trial Site | Miami | Florida | 33126 | — |
| Clinical Trial Site | Miami | Florida | 33135 | — |
| Clinical Trial Site | Miami | Florida | 33137 | — |
| Clinical Trial Site | Miami | Florida | 33165 | — |
| Clinical Trial Site | Stuart | Florida | 34997 | — |
| Clinical Trial Site | West Palm Beach | Florida | 33407 | — |
| Clinical Trial Site | Winter Park | Florida | 32789 | — |
| Clinical Trial Site | Winter Park | Florida | 32792 | — |
| Clinical Trial Site | Decatur | Georgia | 30033 | — |
| Clinical Trial Site | Matthews | North Carolina | 28105 | — |
| Clinical Trial Site | DeSoto | Texas | 75115 | — |
| Clinical Trial Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05074498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2023 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05074498 live on ClinicalTrials.gov.